We show that ErbB3 inhibition by KTN3379 inhibits mainly AKT signaling while cetuximab predominantly attenuates the ERK pathway, providing a mechanistic rationale for the observed enhanced anti-tumor activity of KTN3379 when combined with cetuximab. Here, ERBB3 is linked to neoplasm.